Navigation Links
Hard to Treat Diseases (HTDS) Releases experimental results in the treatment of (MS) Multiple Sclerosis

BELGRADE, March 16 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS) is pleased to announce that a group of investigators (lead by Professor Mirjana Stojiljkovic) from Department of Neurobiology, Institute for Biological Research "Sinisa Stankovic", University of Belgrade, Serbia, (IBISS group) introduced a novel therapeutic approach in treatment of multiple sclerosis (MS), a severe, currently incurable, human disease. The effectiveness of this therapy is shown in experimental animals and has to be proven in people with MS, so that obtained results has to be considered as "experimental." Experimental data obtained on laboratory animals provide the following beneficial effects of the therapy:

    -   The severity of clinical signs of disease was significantly reduced
    -   The pathological changes in the myelin sheath (demyelination) were
        not detected
    -   The reduction of mononuclear cell infiltrates, composed of T cells
        and macrophages/microglia was observed in the spinal cord tissue
    -   The degree of disability was lowered
    -   The duration of the disease was notably shortened
    -   The percentage mortality in severe disease was radically reduced
    -   The severity of treatment side effects was low and disappeared after
        cessation of drug application

In 2005 IBISS group received a prestige reward - The first place and golden medal of Nikola Tesla at the International Festival of Innovations, Know-how and Creativity. The award can be viewed at the company's corporate web site

Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: Certain forward information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competition.

Get the Facts Right. The issuer works hard to continue to keep our shareholders informed, and news is updated frequently via Press Releases, Pink Sheet filings, and updates to our websites. Other websites not sponsored, or recognized by the Company may provide misleading or disinformation to investors in order to manipulate trading patterns for a given stock. Always look for original content from trusted sources, rather than relying on 'excerpts' or discussion boards that may not give you the whole story. The Securities and Exchange Commission requires financial institutions or brokerage firms to provide their clients with documentation, describing the risks of investing in penny stocks.

CONTACT: For medical and scientific dialogue inquiry only, please contact Andrea Zecevic Hbsc. Msci; via e-mail at Andrea Zecevic obtained her degrees at the University of Toronto Canada. Andrea Zecevic is the company's Chief Project Scientist, R&D and the Chief Liaison Director between the China and Serbia operating subsidiaries. For any corporate matters, readers should contact the company directly at

SOURCE Hard to Treat Diseases
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. New Mexico Doctors Now Treating Brain and Prostate Cancer With RapidArc Radiotherapy Technology
2. First Treatment for Muscular Dystrophy in Sight: Scientists Harness Exon-Skipping in Large Animal to Successfully Treat Duchenne Muscular Dystrophy
3. New Treatments Improve Control for Severe Asthma
4. Video: Record Number of Patients Seek Laser Treatments to Take Light-Years Off Their Faces
5. Tens of Thousands of Back Pain Patients Overtreated in Six Health Plans, According to HealthCore Study
6. First treatment for muscular dystrophy in sight: Scientists successfully harness exon-skipping
7. Early results favorable for 5-day radiation treatment of early stage prostate cancer
8. Studies show children can complete treatment for peanut allergies and achieve long-term tolerance
9. Researchers discover ways of integrating treatment of traumatized Tibetan refugee monks
10. HemAway(R) Launches FDA-Cleared Painless Hemorrhoid Treatment Device
11. Victorian Cosmetic Institute to offer Liposuction Treatments
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... The rapid speed at ... people age, more care is needed, especially with Alzheimer’s, dementia and other cognitive ... being overworked. The forgotten part of this equation: 80 percent of medical care ...
(Date:11/27/2015)... ... November 27, 2015 , ... A team of Swiss ... to treat it. Surviving Mesothelioma has just posted the findings on the website. ... Zurich analyzed the cases of 136 mesothelioma patients who were treated with chemotherapy followed ...
(Date:11/27/2015)... ... 27, 2015 , ... An inventor, from Hopkinsville, Ky., thought ... at home, so he invented the patent-pending ELECTRONIC M.D. , The ELECTRONIC M.D. ... doing so, it could help to prevent potential overdose situations. As a result, ...
(Date:11/27/2015)... ... 2015 , ... "When I was traveling, I was very ... "Many people catch diseases simply from sitting on such dirty toilet seats. I ... germs." , He developed the patent-pending QUDRATECS to eliminate the need to sit ...
(Date:11/27/2015)... County, CA (PRWEB) , ... November 27, 2015 , ... ... season , The company is offering customers 10% off of their purchase of lice ... any treatment at full price. According to a company spokesperson. “Finding lice is a ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... , Pays-Bas, November 27, 2015 ... au traitement photodynamique au Bremachlorin contre le cancer ... approche consistant à combiner l,immunothérapie au traitement photodynamique ... --> Une nouvelle approche consistant ... contre le cancer avancé.    ...
(Date:11/27/2015)... 2015 --> ... online. The potential to save costs, improve treatment quality ... from fully exploited as yet. Here, particular emphasis is ... via mobile tablet or directly at the patients, bedside. ... ) -->      (Photo: ...
(Date:11/27/2015)... Ein neuer Kombinationsansatz vereint ... --> Ein neuer Kombinationsansatz vereint Immuntherapie ... --> Ein neuer Kombinationsansatz vereint Immuntherapie ... Clinical Cancer Research vom 6. November ... vom 6. November 2015 berichtet. --> ...
Breaking Medicine Technology: